Technology ID
TAB-3732

MicroRNAs for Cell Line Utilization and Future Therapeutic Application

E-Numbers
E-031-2011-0
Lead Inventor
Shiloach, Joseph (NIDDK)
Co-Inventors
Druz, Aliaksandr (NIDDK)
Chu, Chia (NIDDK)
Betenbaugh, Michael (Johns Hopkins University)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NIDDK
ICs
NIDDK
This technology includes microRNAs for use in cell lines for protein production and potentially future treatments of cancer or diseases related to metabolism. Mmu-miR-466h was identified as a major apoptotic regulator in suspension adapted Chinese Hamster Ovary cells. Mmu-miR-466h was found to have the pro-apoptotic activity by targeting some anti-apoptotic genes for degradation during the exposure of CHO-S cells to the nutrients depleted media. Inhibition of mmu-miR-466h activity resulted in uninhibition of those anti-apoptotic targets and rendered CHO-S more viable with decreased Caspase-3,7 activation during nutrients depleted media incubation. While being pro-apoptotic, mmu-miR466h may also have a tumor suppressor activity in mammalian cells by sensitizing the cancer cells to programmed cell’s death (apoptosis). Mmu-miR-466h is the member of the same microRNA cluster with the pro-apoptotic activity complementary to mmu-miR-466h activity.
Commercial Applications
The stable inhibition of mmu-miR-466h/mmu-miR-466h activity in biotechnology utilized mammalian cell lines will generate more robust and apoptosis resistant cell lines for protein production. Also, mmu-miR-466h/mmi-miR-466h may be considered in treatment of cancer and other diseases related to deregulation in apoptosis program and/or metabolism.

Competitive Advantages
Generation of more robust and apoptosis resistant cell lines for protein production.
Licensing Contact: